Inhibrx Valore dell'impresa
Cos'è Valore dell'impresa di Inhibrx?
Valore dell'impresa di Inhibrx, Inc. è $1.31B
Qual è la definizione di Valore dell'impresa?
Il valore dell'impresa è una misura del valore di mercato totale di un'azienda. È calcolato come capitalizzazione di mercato con debito, interessi di minoranza e azioni privilegiate al netto delle disponibilità liquide e mezzi equivalenti.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Valore dell'impresa di aziende nel Health Care settore su NASDAQ rispetto a Inhibrx
Cosa fa Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Aziende con valore dell'impresa simili a Inhibrx
- Godrej Agrovet ha Valore dell'impresa di $1.31B
- Savencia SA ha Valore dell'impresa di $1.31B
- Green Plains Inc ha Valore dell'impresa di $1.31B
- Network18 Media & Investments ha Valore dell'impresa di $1.31B
- Welspun India ha Valore dell'impresa di $1.31B
- GIC Housing Finance ha Valore dell'impresa di $1.31B
- Inhibrx ha Valore dell'impresa di $1.31B
- Magyar Telekom Telecommunications Plc ha Valore dell'impresa di $1.31B
- Desktop Metal ha Valore dell'impresa di $1.31B
- PTC India ha Valore dell'impresa di $1.32B
- Score Media and Gaming ha Valore dell'impresa di $1.32B
- Ironwood Pharmaceuticals Inc ha Valore dell'impresa di $1.32B
- Social Capital Hedosophia Holdi ha Valore dell'impresa di $1.32B